Heterogeneity, consistency and model fit should be assessed in Bayesian network meta-analysis

We read with deep interest the article by Wang et al aimed to compare the efficacy of 20 non-steroidal anti-inflammatory drugs (NSAIDs) in the short-term treatment of ankylosing spondylitis (AS). This Bayesian network meta-analysis indicated that etoricoxib was more effective in reducing pain in AS than some other NSAIDs. The result was very useful in the decision-making process, especially for pain relief in treating patients with AS. However, there are some worthwhile issues that need to be explored.

First, it is commonly agreed that meta-analysis, including network meta-analysis, should assess heterogeneity, which may be defined as the presence of variation in true effect sizes underlying the different studies. Unfortunately, however, heterogeneity was not assessed in this network meta-analysis. Between-study heterogeneity indicates the presence of effect modifiers, and variability in relative treatment effects has a bad impact on the external validity of trial evidence, and limits the ability to generalise from the results. There may exist some impact on the external validity of trial evidence, and limits the ability to generalise from the results.2 There may exist some impact on the external validity of trial evidence, and limits the ability to generalise from the results.2 There may exist some impact on the external validity of trial evidence, and limits the ability to generalise from the results.2 However, it is highly likely that there was heterogeneity. In addition, some extremely important covariates, such as drug dose, for the same NSAID should be considered in this network meta-analysis. The authors should consider the relative contribution of true variability and random variation due to biases. Perhaps Bayesian meta-regression should be conducted to consider the covariates. Second, unlike classical meta-analysis, Bayesian network meta-analysis combines all available direct and indirect evidences on the relative treatment effects. Inconsistency can also be caused by the effect modifiers and specifically by an imbalance in the distribution of effect modifiers in the direct and indirect evidence. Consistency assessing is also worthy of expectation. Third, a better model fit can reduce the inconsistency between direct and indirect evidences. Thus, model fit should be assessed to assure the reliability of the results as well. In order to provide reliable evidence, a checklist, which is intended for those who review evidence syntheses and those submitting syntheses, should be recommended.

Above all, perhaps, heterogeneity, consistency and model fit should be assessed in this Bayesian network meta-analysis to make the results more reliable for guiding clinical practice. We respect the great contributions of the authors, and we also very much look forward to seeing authors’ response to these issues.

REFERENCES
Heterogeneity, consistency and model fit should be assessed in Bayesian network meta-analysis

Jie Wei, Chao Zeng and Guang-hua Lei

*Ann Rheum Dis* 2016 75: e5 originally published online October 15, 2015

Updated information and services can be found at:
http://ard.bmj.com/content/75/1/e5

These include:

**References**
This article cites 5 articles, 0 of which you can access for free at:
http://ard.bmj.com/content/75/1/e5#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/